Avita Medical Inc. (NASDAQ: RCEL) is a Healthcare company (Medical - Devices) with a market capitalization of $402M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Avita Medical Inc. had a Maz Rating of 3.51 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Valuation (4.61), among the most attractively valued in its sector; its weakest was Financial Health (1.46), among the weakest in its sector. The other factors: Profitability 3.50 (above most of its sector); Momentum 3.44 (around the middle of its sector); Growth 2.76 (around the middle of its sector). The current rating is for members: log in to see it.
At $16.20, Avita Medical Inc. trades at 4.8x sales. Over the last twelve months it generated about $83M of revenue and a net loss of $29M. It runs a gross margin of 82.4%, an operating margin of -33.9% and a net margin of -42.6%. It shows return on equity of 146.4%, return on invested capital of -120.8% and a free cash flow yield of -4.5%. On the balance sheet: a debt-to-equity ratio of -1.52 and a current ratio of 1.20. Over the past 52 weeks the share price ranged from $3.22 to $18.43, with a beta of 2.01.
Avita Medical Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.